Seito Biologics

SEITO Biologics AG is a biotechnology company focused on developing targeted cytokine therapies to address autoimmune diseases. The company operates in the biopharmaceutical sector, leveraging discoveries from the Department of Immunology at the University of Zurich. As a spin-off from the university, SEITO Biologics aims to restore immune balance by reinforcing regulatory T cells (Tregs) through their proprietary Treg cell engagers, known as TREX. The business model involves the development and commercialization of IL-2 immunotherapies that selectively activate Tregs while sparing cytotoxic effector immune cells. SEITO Biologics generates revenue through the licensing of its patented therapies and potential partnerships with pharmaceutical companies. The company serves clients in the healthcare industry, particularly those involved in treating autoimmune conditions. SEITO Biologics' leadership includes experienced scientists and clinicians, such as CEO Onur Boyman, who has contributed significantly to the field of IL-2 immunotherapy. The company is committed to advancing its clinical candidates and expanding its impact on the treatment of autoimmune diseases.

Keywords: cytokine therapies, regulatory T cells, autoimmune diseases, IL-2 immunotherapy, Treg cell engagers, biopharmaceutical, University of Zurich, clinical trials, patent licensing, healthcare.